235 related articles for article (PubMed ID: 25869965)
21. Protective immunity in mice achieved with dry powder formulation and alternative delivery of plague F1-V vaccine.
Huang J; D'Souza AJ; Alarcon JB; Mikszta JA; Ford BM; Ferriter MS; Evans M; Stewart T; Amemiya K; Ulrich RG; Sullivan VJ
Clin Vaccine Immunol; 2009 May; 16(5):719-25. PubMed ID: 19261773
[TBL] [Abstract][Full Text] [Related]
22. Improved vaccine-induced immune responses via a ROS-triggered nanoparticle-based antigen delivery system.
Liang X; Duan J; Li X; Zhu X; Chen Y; Wang X; Sun H; Kong D; Li C; Yang J
Nanoscale; 2018 May; 10(20):9489-9503. PubMed ID: 29675543
[TBL] [Abstract][Full Text] [Related]
23. Mutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from Yersinia pestis as next generation plague vaccines.
Tao P; Mahalingam M; Kirtley ML; van Lier CJ; Sha J; Yeager LA; Chopra AK; Rao VB
PLoS Pathog; 2013; 9(7):e1003495. PubMed ID: 23853602
[TBL] [Abstract][Full Text] [Related]
24. A liposomal vaccine promotes strong adaptive immune responses via dendritic cell activation in draining lymph nodes.
Agallou M; Margaroni M; Tsanaktsidou E; Badounas F; Kammona O; Kiparissides C; Karagouni E
J Control Release; 2023 Apr; 356():386-401. PubMed ID: 36893900
[TBL] [Abstract][Full Text] [Related]
25. Nanoparticles with CD44 Targeting and ROS Triggering Properties as Effective in Vivo Antigen Delivery System.
Liang X; Li X; Duan J; Chen Y; Wang X; Pang L; Kong D; Song B; Li C; Yang J
Mol Pharm; 2018 Feb; 15(2):508-518. PubMed ID: 29323913
[TBL] [Abstract][Full Text] [Related]
26. Cell-mediated immune response and Th/Th cytokine profile of B-T constructs of F1 and V antigen of Yersinia pestis.
Gupta G; Khan AA; Rao DN
Scand J Immunol; 2010 Mar; 71(3):186-98. PubMed ID: 20415784
[TBL] [Abstract][Full Text] [Related]
27. Reduction Sensitive PEG Hydrogels for Codelivery of Antigen and Adjuvant To Induce Potent CTLs.
Kapadia CH; Tian S; Perry JL; Luft JC; DeSimone JM
Mol Pharm; 2016 Oct; 13(10):3381-3394. PubMed ID: 27551741
[TBL] [Abstract][Full Text] [Related]
28. Humoral and cellular immune correlates of protection against bubonic plague by a live Yersinia pseudotuberculosis vaccine.
Demeure CE; Derbise A; Guillas C; Gerke C; Cauchemez S; Carniel E; Pizarro-Cerdá J
Vaccine; 2019 Jan; 37(1):123-129. PubMed ID: 30467064
[TBL] [Abstract][Full Text] [Related]
29. Protective immunity against a lethal respiratory Yersinia pestis challenge induced by V antigen or the F1 capsular antigen incorporated into adenovirus capsid.
Boyer JL; Sofer-Podesta C; Ang J; Hackett NR; Chiuchiolo MJ; Senina S; Perlin D; Crystal RG
Hum Gene Ther; 2010 Jul; 21(7):891-901. PubMed ID: 20180652
[TBL] [Abstract][Full Text] [Related]
30. Complete Protection against Pneumonic and Bubonic Plague after a Single Oral Vaccination.
Derbise A; Hanada Y; Khalifé M; Carniel E; Demeure CE
PLoS Negl Trop Dis; 2015; 9(10):e0004162. PubMed ID: 26473734
[TBL] [Abstract][Full Text] [Related]
31. Targeted Codelivery of an Antigen and Dual Agonists by Hybrid Nanoparticles for Enhanced Cancer Immunotherapy.
Zhang L; Wu S; Qin Y; Fan F; Zhang Z; Huang C; Ji W; Lu L; Wang C; Sun H; Leng X; Kong D; Zhu D
Nano Lett; 2019 Jul; 19(7):4237-4249. PubMed ID: 30868883
[TBL] [Abstract][Full Text] [Related]
32. Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge.
Wang S; Goguen JD; Li F; Lu S
Vaccine; 2011 Sep; 29(39):6802-9. PubMed ID: 21199697
[TBL] [Abstract][Full Text] [Related]
33. Improving the Th1 cellular efficacy of the lead Yersinia pestis rF1-V subunit vaccine using SA-4-1BBL as a novel adjuvant.
Dinc G; Pennington JM; Yolcu ES; Lawrenz MB; Shirwan H
Vaccine; 2014 Sep; 32(39):5035-40. PubMed ID: 25045812
[TBL] [Abstract][Full Text] [Related]
34. Covalently stabilized trimethyl chitosan-hyaluronic acid nanoparticles for nasal and intradermal vaccination.
Verheul RJ; Slütter B; Bal SM; Bouwstra JA; Jiskoot W; Hennink WE
J Control Release; 2011 Nov; 156(1):46-52. PubMed ID: 21784113
[TBL] [Abstract][Full Text] [Related]
35. Antigen delivery via hydrophilic PEG-b-PAGE-b-PLGA nanoparticles boosts vaccination induced T cell immunity.
Rietscher R; Schröder M; Janke J; Czaplewska J; Gottschaldt M; Scherließ R; Hanefeld A; Schubert US; Schneider M; Knolle PA; Lehr CM
Eur J Pharm Biopharm; 2016 May; 102():20-31. PubMed ID: 26940132
[TBL] [Abstract][Full Text] [Related]
36. Vaccination with live Yersinia pestis primes CD4 and CD8 T cells that synergistically protect against lethal pulmonary Y. pestis infection.
Philipovskiy AV; Smiley ST
Infect Immun; 2007 Feb; 75(2):878-85. PubMed ID: 17118978
[TBL] [Abstract][Full Text] [Related]
37. Lipid A mimetics are potent adjuvants for an intranasal pneumonic plague vaccine.
Airhart CL; Rohde HN; Hovde CJ; Bohach GA; Deobald CF; Lee SS; Minnich SA
Vaccine; 2008 Oct; 26(44):5554-61. PubMed ID: 18722493
[TBL] [Abstract][Full Text] [Related]
38. Controlled analysis of nanoparticle charge on mucosal and systemic antibody responses following pulmonary immunization.
Fromen CA; Robbins GR; Shen TW; Kai MP; Ting JP; DeSimone JM
Proc Natl Acad Sci U S A; 2015 Jan; 112(2):488-93. PubMed ID: 25548169
[TBL] [Abstract][Full Text] [Related]
39. A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague.
Tao P; Mahalingam M; Zhu J; Moayeri M; Sha J; Lawrence WS; Leppla SH; Chopra AK; Rao VB
mBio; 2018 Oct; 9(5):. PubMed ID: 30327445
[No Abstract] [Full Text] [Related]
40. Cationic polymer modified PLGA nanoparticles encapsulating Alhagi honey polysaccharides as a vaccine delivery system for ovalbumin to improve immune responses.
Wusiman A; Gu P; Liu Z; Xu S; Zhang Y; Hu Y; Liu J; Wang D; Huang X
Int J Nanomedicine; 2019; 14():3221-3234. PubMed ID: 31123399
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
